

Status: Currently Official on 15-Feb-2025

Official Date: Official as of 01-Mar-2024

Document Type: USP Monographs

DocId: GUID-31E7AD95-1A85-4CD5-BD2E-788F1BEA1FA4_5_en-US


DOI: https://doi.org/10.31003/USPNF_M53440_05_01

DOI Ref: prb0p

© 2025 USPC

Do not distribute

Metolazone

C₁₆H₁₆ClN₃O₃S 365.83

6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-;

7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide CAS RN[®]: 17560-51-9; UNII: TZ7V40X7VX.

DEFINITION

Metolazone contains NLT 97.0% and NMT 102.0% of metolazone (C₁₆H₁₆ClN₃O₃S), calculated on the dried basis.

IDENTIFICATION

• **A. SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Infrared Spectroscopy*: **197K**• **B. SPECTROSCOPIC IDENTIFICATION TESTS** (197), *Ultraviolet-Visible Spectroscopy*: **197U****Sample solution:** 5 µg/mL in methanol**Acceptance criteria:** Meets the requirements• **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

PROCEDURE

Protect all solutions of Metolazone from light.

Buffer: 5.4 g/L of monobasic potassium phosphate. Adjust with phosphoric acid to a pH of 3.0.**Mobile phase:** Acetonitrile, methanol, and *Buffer* (10:25:65)**Standard stock solution:** 0.5 mg/mL of [USP Metolazone RS](#) in tetrahydrofuran**Standard solution:** 0.05 mg/mL of [USP Metolazone RS](#) in alcohol from the *Standard stock solution***Sample stock solution:** 1 mg/mL of Metolazone in tetrahydrofuran**Sample solution:** 0.05 mg/mL of Metolazone in alcohol from the *Sample stock solution*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)**Mode:** LC**Detector:** UV 230 nm**Column:** 4.6-mm × 25-cm; 10-µm packing L1**Flow rate:** 1.5 mL/min**Injection volume:** 15 µL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.4**Relative standard deviation:** NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*Calculate the percentage of metolazone (C₁₆H₁₆ClN₃O₃S) in the portion of sample taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of metolazone from the *Sample solution* r_S = peak response of metolazone from the *Standard solution* C_S = concentration of [USP Metolazone RS](#) in the *Standard solution* (µg/mL)

C_U = concentration of Metolazone in the *Sample solution* (µg/mL)

Acceptance criteria: 97.0%–102.0% on the dried basis

IMPURITIES

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

Change to read:

- **ORGANIC IMPURITIES**

Buffer and Mobile phase: Proceed as directed in the Assay.

Standard stock solution: 0.48 mg/mL of [USP Metolazone RS](#) in tetrahydrofuran

Standard solution: 6 µg/mL of [USP Metolazone RS](#) in alcohol from the *Standard stock solution*

Sample solution: 0.6 mg/mL of Metolazone, prepared as follows. Dissolve a suitable amount of Metolazone with tetrahydrofuran in 50% of the total volume, and dilute with alcohol to volume.

Chromatographic system: Proceed as directed in the Assay, except for the following:

Column: 4.6-mm × 25-cm; 5-µm packing ▲L1▲ (ERR 1-Mar-2024)

Run time: NLT 3.5 times the retention time of metolazone

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.4

Relative standard deviation: NMT 5.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of each individual impurity in the portion of sample taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

r_U = peak response of each individual impurity from the *Sample solution*

r_S = peak response of metolazone from the *Standard solution*

C_S = concentration of [USP Metolazone RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Metolazone in the *Sample solution* (mg/mL)

F = relative response factor of each individual impurity (see [Table 1](#))

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Desmethyl metolazone ^a	0.7	1.0	0.5
Metolazone benzamide analog ^b	0.8	0.83	0.5
Metolazone	1.0	1.0	—
<i>meta</i> -Metolazone ^c	1.3	0.91	0.5
<i>para</i> -Metolazone ^d	1.4	0.91	0.5
Didehydrometolazone ^e	1.5	0.83	0.5
Any other individual impurity	—	—	0.10
Total impurities ^f	—	—	1.0

^a 7-Chloro-2-methyl-4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazoline-6-sulfonamide.

^b 2-Amino-4-chloro-5-sulfamoyl-*N*-(*o*-tolyl)benzamide.

- c 7-Chloro-2-methyl-4-oxo-3-(*m*-tolyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide.
- d 7-Chloro-2-methyl-4-oxo-3-(*p*-tolyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide.
- e 7-Chloro-2-methyl-4-oxo-3-(*o*-tolyl)-3,4-dihydroquinazoline-6-sulfonamide.
- f Sum of all individual impurities. Disregard any peaks less than 0.05%.

SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

Analysis: Dry a sample at 105° for 2 h.
Acceptance criteria: NMT 1.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.
- [USP REFERENCE STANDARDS \(11\)](#).
[USP Metolazone RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METOLAZONE	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 38(4)

Current DocID: GUID-31E7AD95-1A85-4CD5-BD2E-788F1BEA1FA4_5_en-US
DOI: https://doi.org/10.31003/USPNF_M53440_05_01
DOI ref: [prb0p](#)

OFFICIAL